摘要
Abstract
Objective To investigate the efficacy and safety of the combined treatment of enoxaparin tirofiban for acute myocardial infarction. Methods 120 patients with acute myocardial infarction in our hospital from November 2011 to January 2013 were randomly divided into treatment group and control group, with 60 cases in each group. These patients were given intravenous thrombolysis, perindopril or losartan, nitroglycerin, metoprolol, clopidogrel, atorvastatin calcium, aspirin, enoxaparin and other conventional treatment. The treatment group were given intravenous infusion of tirofiban after thrombolysis, firstly 0.4 μg·kg-1·min-1, 30 min, and then 0.15 μg·kg-1·min-1. Bleeding, infarction recanalization and adverse cardiac events (MACE) were observed. Results The indirect recanalization and direct recanalization in the treatment group were better than those in the control group. There was significant difference between the effective rates between the two groups (P <0.05). The number of patients with bleeding in the treatment group was significantly larger than that in the control group (P <0.05). Conclusions Tirofiban combined with intravenous thrombolysis with urokinase for the treatment of acute myocardial infarction is safe, effective, which is worthy of clinical application.关键词
依诺肝素/替罗非班/急性心肌梗死Key words
Enoxaparin/Tirofiban/Acute myocardial infarction分类
医药卫生
